Allogene Therapeutics, Inc. (ALLO)

NASDAQ: ALLO · Real-Time Price · USD

1.980

-0.005 (-0.25%)

At close: Sep 2, 2026, 4:00 PM EDT

1.990

+0.010 (0.51%)

Pre-market: Sep 3, 2026, 9:13 AM EDT

Allogene Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	38.63	51.69	75.22	83.16	61.9	173.31
Short-Term Investments	293.98	198.52	217.26	365.54	455.42	283.99
Cash & Short-Term Investments	332.6	250.21	292.48	448.7	517.32	457.3
Cash Growth	21.78%	-14.45%	-34.82%	-13.26%	13.12%	-44.76%
Other Receivables	2.2	1.5	1.9	1.7	3.3	6
Receivables	2.2	1.5	1.9	1.7	3.3	6
Prepaid Expenses	5.2	6.04	9.01	8.72	8.2	8.02
Total Current Assets	340	257.75	303.39	459.12	528.82	471.32
Property, Plant & Equipment	105.12	112.73	131.26	163.18	196.43	181.02
Long-Term Investments	90.99	8.04	80.67	3.65	79.47	370.18
Other Long-Term Assets	13.98	37.39	33.39	16.9	16.86	16.11
Total Assets	550.09	415.91	548.71	642.84	821.58	1,039

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	5.96	4.27	5.39	5.9	13.89	10.26
Accrued Expenses	17.11	17.64	21.55	21.98	29.73	29.65
Current Portion of Leases	8.66	8.21	7.51	6.78	6	3.2
Current Unearned Revenue	-	-	-	0.09	0.1	0.42
Other Current Liabilities	-	2.4	1.07	2.34	4.02	4.65
Total Current Liabilities	31.73	32.51	35.52	37.08	53.73	48.17
Long-Term Leases	70.35	75.05	83.25	88.35	95.12	69.93
Other Long-Term Liabilities	11.84	15.8	7.76	5.18	5.85	4.13
Total Liabilities	113.92	123.36	126.53	130.6	154.7	122.23

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.35	0.23	0.21	0.17	0.14	0.14
Additional Paid-In Capital	2,532	2,303	2,242	2,075	1,912	1,822
Retained Earnings	-2,096	-2,011	-1,820	-1,562	-1,235	-903.35
Comprehensive Income & Other	-0.52	0.27	-0.09	-0.96	-9.93	-2.57
Shareholders' Equity	436.18	292.54	422.18	512.23	666.88	916.41
Total Liabilities & Equity	550.09	415.91	548.71	642.84	821.58	1,039

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	79.01	83.25	90.76	95.12	101.12	73.13
Net Cash (Debt)	253.6	166.96	201.72	353.58	416.2	384.17
Net Cash Growth	36.25%	-17.23%	-42.95%	-15.05%	8.34%	-50.37%
Net Cash Per Share	1.00	0.76	1.04	2.25	2.91	2.83
Filing Date Shares Outstanding	345.49	243.78	217.26	169.09	144.5	142.75
Total Common Shares Outstanding	345.35	229.41	212.21	168.64	144.44	142.62
Working Capital	308.27	225.24	267.86	422.04	475.1	423.15
Book Value Per Share	1.26	1.28	1.99	3.04	4.62	6.43
Tangible Book Value	436.18	292.54	422.18	512.23	666.88	916.41
Tangible Book Value Per Share	1.26	1.28	1.99	3.04	4.62	6.43
Machinery	37.83	37.84	40.47	41.94	41.15	37.96
Construction In Progress	-	-	-	-	0.03	0.04
Leasehold Improvements	107.54	107.54	108.13	108.62	108.55	108.35

SEC Filings: 10-K · 10-Q